The problem or maybe even deliberately not wanted at all Hopper companies is the lack of big international instos / funds. The science would easily justify a holding. Hopper hired experts in that field, Eckstein and Shah, but so far they failed to deliver. The AGM showed just 30% voted, that means 70% were not interested at all. With a spill on the cards it would have been a motivation for either camp to vote to get their preference over the line. Let's assume Hopper activated all votes under his control then he probably can only count on about 25% - 28 % of votes. So why didn't the 70% vote? If those were hidden accounts by just a few bigger players then I am sure we would have seen at least 90% participation to either support or topple the board. I conclude that the thousands of nominee accounts are actually just that, small to mid sized holders / nominees using those bigger brokers to invest. We all want the sp to reflect the fair value without giving away anything to Big Pharma at this stage. The only way to do so is by attracting investor $$$$ from overseas. The question is, why aren't Hopper, Eckstein, Shah able or willing despite their listed experiences and former successes.
Would you guys as a fund manger, when Hopper knocked at your door, accept offers for a USD 6.6m placement for the world's most effective Brain Cancer treatment (CHM), USD 66m placement for Vaxinia, Azer-Cel, PD1-Vaxx and Her-Vaxx and more applications of those platforms? I would, as the future financial gains from current sp levels are enormous. The big question remians, why can't they attract the big bucks when the science world is already "demanding" the treatments ( FDA support, trial participants, oncologists in AUS, USA, Europe ).
Something is not right, to me it looks like Hopper and Co are trying to avoid any international holdings, using Bell Potter over and over again. Presenting incredible science and data at the world stage and yet, hardly any USD / EURO buying IMU shares. There are always brainy people out there being able to spot bargains with huge LT gains and yet they neither have been invited nor asked to invest.
I still can't understand that the "3 IMU-Bucketeers" aren't able to sell superior data to the world when the users ( oncologists / patients ) already have experienced the benefits.
Regarding Her-Vaxx, I expect Hopper to have met Prof Wiedermann while he has been in Europe. She got very close ties with Pfizer due to her work coordinating the European Covid response and got a deep inside into the mRNA tech. The Wiedermann / Tobias team is not asleep when it comes to explore new ways / combinations. We could get some news from that connection. As LC said, stay tuned.
GLTA
Expand
(20min delay)